Baxter International (BAX) Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BAX, but not buy additional shares or sell existing shares.
View BAX analyst ratings or view top-rated stocks.

14 Wall Street analysts have issued 1 year target prices for Baxter International's shares. Their BAX share price forecasts range from $43.00 to $70.00. On average, they predict the company's share price to reach $52.38 in the next year. This suggests a possible upside of 26.7% from the stock's current price.
View analysts price targets for BAX or view top-rated stocks among Wall Street analysts.

Baxter International's stock was trading at $50.97 at the beginning of 2023. Since then, BAX shares have decreased by 18.9% and is now trading at $41.33.
View the best growth stocks for 2023 here.

Baxter International saw a decline in short interest in May. As of May 15th, there was short interest totaling 5,710,000 shares, a decline of 5.5% from the April 30th total of 6,040,000 shares. Based on an average trading volume of 5,860,000 shares, the short-interest ratio is presently 1.0 days. Currently, 1.1% of the shares of the stock are sold short.
View Baxter International's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our BAX earnings forecast.

Baxter International Inc. (NYSE:BAX) announced its quarterly earnings data on Thursday, April, 27th. The medical instruments supplier reported $0.59 EPS for the quarter, topping the consensus estimate of $0.48 by $0.11. The medical instruments supplier had revenue of $3.65 billion for the quarter, compared to the consensus estimate of $3.60 billion. Baxter International had a negative net margin of 16.34% and a positive trailing twelve-month return on equity of 24.29%. The firm's revenue was down 1.6% on a year-over-year basis. During the same period last year, the company earned $0.93 EPS.
Read the conference call transcript.

Baxter International announced a quarterly dividend on Monday, May 1st. Investors of record on Friday, June 2nd will be given a dividend of $0.29 per share on Monday, July 3rd. This represents a $1.16 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date is Thursday, June 1st.
Read our dividend analysis for BAX.

ETFs with the largest weight of Baxter International (NYSE:BAX) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Gabelli Love Our Planet & People ETF (LOPP), Invesco Zacks Mid-Cap ETF (CZA), Invesco S&P 500 Equal Weight Health Care ETF (RYH), SPDR S&P Health Care Equipment ETF (XHE), First Trust Indxx Medical Devices ETF (MDEV), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and iShares MSCI Global Sustainable Development Goals ETF (SDG).

Baxter International (NYSE:BAX) pays an annual dividend of $1.16 per share and currently has a dividend yield of 2.81%.
Read our dividend analysis for BAX.

Baxter International issued an update on its second quarter 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of $0.59-$0.61 for the period, compared to the consensus EPS estimate of $0.60. The company issued revenue guidance of $3.78 billion-$3.82 billion, compared to the consensus revenue estimate of $3.77 billion.

506 employees have rated Baxter International Chief Executive Officer José (Joe) Almeida on Glassdoor.com. José (Joe) Almeida has an approval rating of 85% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), Abbott Laboratories (ABT), Procter & Gamble (PG), AT&T (T) and Verizon Communications (VZ).

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

Baxter International's stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.77%), Ameriprise Financial Inc. (1.03%), Bank of New York Mellon Corp (0.78%), Cooke & Bieler LP (0.64%), Coho Partners Ltd. (0.40%) and Sumitomo Mitsui Trust Holdings Inc. (0.28%). Insiders that own company stock include Albert P L Stroucken, Andrew Frye, Brian Stevens, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason and John D Forsyth.
View institutional ownership trends.

Shares of BAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BAX stock can currently be purchased for approximately $41.33.

Baxter International (NYSE:BAX) has a market capitalization of $20.91 billion and generates $15.11 billion in revenue each year. The medical instruments supplier earns $-2,433,000,000.00 in net income (profit) each year or ($4.88) on an earnings per share basis.

The company employs 60,000 workers across the globe.

Baxter International's mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The official website for the company is www.baxter.com. The medical instruments supplier can be reached via phone at (224) 948-2000, via email at global_corp_investor_relations@baxter.com, or via fax at 224-948-1813.